CLINICAL_TRIALS
trial_result
· 2023-05-23
Clinical Trial Update: Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity [Phase 3]
Summary
Phase 3 trial evaluating setmelanotide for leptin receptor deficiency obesity has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Rhythm Pharmaceuticals, Inc. | Conditions: Leptin Receptor Deficiency Obesity | Phase 3 | Status: COMPLETED | Results posted: 2023-05-23